Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in: Experimental Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention

Authors: Sih-han Wang, Shiaw-Yih Lin

Published in: Experimental Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

In past decades, cancer patient survival has been improved with earlier detection and advancements in therapy. However, many patients who exhibit no clinical symptoms after frontline therapy subsequently suffer, often many years later, aggressive tumor recurrence. Cancer recurrence represents a critical clinical challenge in effectively treating malignancies and for patients’ quality of life. Tumor cell dormancy may help to explain treatment resistance and recurrence or metastatic reactivation. Understanding the dormant stage of tumor cells may help in discovering ways to maintain the dormant state or permanently eliminate dormant residual disseminated tumor cells. Over the past decade, numerous studies indicate that various mechanisms of tumor dormancy exist, including cellular dormancy (quiescence), angiogenic dormancy, and immunologic dormancy. In this short review, we summarize recent experimental and clinical evidence for these three mechanisms and other possible tumor microenvironment mechanisms that may influence tumor dormancy.
Appendix
Available only for authorised users
Literature
1.
Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004, 10: 8152–8162.PubMedCrossRef
2.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281: 1591–1597.PubMedCrossRef
3.
Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000, 164: 101–105.PubMedCrossRef
4.
Faries MB, Steen S, Ye X, Sim M, Morton DL: Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 2013, 217: 27–34. discussion 34–26PubMedCentralPubMedCrossRef
5.
Callaway MP, Briggs JC: The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg 1989, 42: 46–49.PubMedCrossRef
6.
Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood 1998, 92: 1184–1190.PubMed
7.
Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J: Immunotherapy of Non-Hodgkin’s lymphomas. Hematology Am Soc Hematol Educ Program 2001, 2001: 221–240.CrossRef
8.
Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K: Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005, 11: 3678–3685.PubMedCrossRef
9.
Patrikidou A, Chabaud S, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Domont J, Perol D, Blay JY, Le Cesne A, French Sarcoma G: Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013, 24: 1087–1093.PubMedCrossRef
10.
Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL, Zewe JP, Wozniak A, Mehalek KR, Korzeniewski N, Seneviratne DS, Schoffski P, Debiec-Rychter M, Decaprio JA, Duensing A: The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis. Cancer Res 2013, 73: 5120–5129.PubMedCrossRef
11.
Mellor HR, Ferguson DJ, Callaghan R: A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer 2005, 93: 302–309.PubMedCentralPubMedCrossRef
12.
Rameshwar P: Breast cancer cell dormancy in bone marrow: potential therapeutic targets within the marrow microenvironment. Expert Rev Anticancer Ther 2010, 10: 129–132.PubMedCrossRef
13.
Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C: Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012, 30: 525–532.PubMedCrossRef
14.
Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8: 329–340.PubMedCrossRef
15.
Zbigniew Darzynkiewicz GJ, Edward F: Srour: differential staining of DNA and RNA. Current Protocols in Cytometry 2004.
16.
Zou P, Yoshihara H, Hosokawa K, Tai I, Shinmyozu K, Tsukahara F, Maru Y, Nakayama K, Nakayama KI, Suda T: p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 2011, 9: 247–261.PubMedCrossRef
17.
Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J: Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 2007, 110: 1631–1638.PubMedCentralPubMedCrossRef
18.
19.
Schmit F, Korenjak M, Mannefeld M, Schmitt K, Franke C, von Eyss B, Gagrica S, Hanel F, Brehm A, Gaubatz S: LINC, a human complex that is related to pRB-containing complexes in invertebrates regulates the expression of G2/M genes. Cell Cycle 2007, 6: 1903–1913.PubMedCrossRef
20.
Sadasivam S, Duan S, DeCaprio JA: The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev 2012, 26: 474–489.PubMedCentralPubMedCrossRef
21.
Hurford RK Jr, Cobrinik D, Lee MH, Dyson N: pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 1997, 11: 1447–1463.PubMedCrossRef
22.
Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM, Rempel RE: E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell 2000, 6: 729–735.PubMedCrossRef
23.
Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA: DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 2011, 25: 801–813.PubMedCentralPubMedCrossRef
24.
Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM: A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006, 20: 47–64.PubMedCentralPubMedCrossRef
25.
Deng X, Ewton DZ, Friedman E: Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species. Cancer Res 2009, 69: 3317–3324.PubMedCentralPubMedCrossRef
26.
27.
Satchi-Fainaro R, Ferber S, Segal E, Ma L, Dixit N, Ijaz A, Hlatky L, Abdollahi A, Almog N: Prospective identification of glioblastoma cells generating dormant tumors. PLoS ONE 2012, 7: e44395.PubMedCentralPubMedCrossRef
28.
Straume O, Shimamura T, Lampa MJ, Carretero J, Oyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN: Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci USA 2012, 109: 8699–8704.PubMedCentralPubMedCrossRef
29.
Patel SA, Ramkissoon SH, Bryan M, Pliner LF, Dontu G, Patel PS, Amiri S, Pine SR, Rameshwar P: Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci Rep 2012, 2: 906.PubMedCentralPubMedCrossRef
30.
Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, Greco SJ, Bryan M, Patel PS, Rameshwar P: Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 2011, 71: 1550–1560.PubMedCrossRef
31.
Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D, Bissell MJ: The perivascular niche regulates breast tumour dormancy. Nature cell biology 2013, 15: 807–817.PubMedCrossRef
32.
Franses JW, Baker AB, Chitalia VC, Edelman ER: Stromal endothelial cells directly influence cancer progression. Sci Transl Med 2011, 3: 66ra65.CrossRef
33.
Chen H, Ko JM, Wong VC, Hyytiainen M, Keski-Oja J, Chua D, Nicholls JM, Cheung FM, Lee AW, Kwong DL, Chiu PM, Zabarovsky ER, Tsao SW, Tao Q, Kan R, Chan SH, Stanbridge EJ, Lung ML: LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma. Cancer Lett 2012, 325: 89–98.PubMedCrossRef
34.
Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Lowik CW, van der Pluijm G: BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007, 171: 1047–1057.PubMedCentralPubMedCrossRef
35.
Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150: 764–779.PubMedCentralPubMedCrossRef
36.
Boyerinas B, Zafrir M, Yesilkanal AE, Price TT, Hyjek EM, Sipkins DA: Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 2013, 121: 4821–4831.PubMedCentralPubMedCrossRef
37.
38.
39.
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD: Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450: 903–907.PubMedCrossRef
40.
Hensel JA, Flaig TW, Theodorescu D: Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol 2013, 10: 41–51.PubMedCrossRef
41.
Gelao L, Criscitiello C, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, Curigliano G: Tumour dormancy and clinical implications in breast cancer. Ecancermedicalscience 2013, 7: 320.PubMedCentralPubMed
42.
43.
Wu X, Peng M, Huang B, Zhang H, Wang H, Huang B, Xue Z, Zhang L, Da Y, Yang D, Yao Z, Zhang R: Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett 2013, 340: 124–133.PubMedCrossRef
44.
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ: Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012, 72: 3987–3996.PubMedCentralPubMedCrossRef
45.
Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M: IL-23 promotes tumour incidence and growth. Nature 2006, 442: 461–465.PubMedCrossRef
46.
47.
Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA: ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 2011, 17: 5850–5857.PubMedCentralPubMedCrossRef
48.
Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK: Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 2004, 64: 7336–7345.PubMedCrossRef
49.
Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003, 63: 1684–1695.PubMed
50.
Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L: Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001, 12: 863–879.PubMedCentralPubMedCrossRef
51.
Allgayer H, Aguirre-Ghiso JA: The urokinase receptor (u-PAR)–a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 2008, 116: 602–614.PubMedCentralPubMedCrossRef
52.
53.
54.
Kim RS, Avivar-Valderas A, Estrada Y, Bragado P, Sosa MS, Aguirre-Ghiso JA, Segall JE: Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS ONE 2012, 7: e35569.PubMedCentralPubMedCrossRef
Metadata
Title
Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention
Authors
Sih-han Wang
Shiaw-Yih Lin
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2013
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/2162-3619-2-29

Other articles of this Issue 1/2013

Experimental Hematology & Oncology 1/2013 Go to the issue

Case report

Cardiac metastasis from yolk sac tumor: case report and review

Research

ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma

Research

Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma

Research

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

Research

Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia

Research

Clinical and laboratory characteristics of adolescents with platelet function disorders and heavy menstrual bleeding
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits